Eyevance Pharmaceuticals announced the acquisition of Freshkote—a family of lubricant eye drops from Focus Laboratories. Eyevance acquired Freshkote and all of its formulations, including the preservative-free, multidose bottle and single-unit vials to market and commercialize worldwide.
Terms of the deal were not disclosed.
Freshkote PF is designed to support the integrity of all three layers of the tear film, offering dry eye patients relief from symptoms. Freshkote PF combats evaporation on the ocular surface with a patented polymer blend formulated to mimic the lipid layer of the tear film. Notably, due to its nonirritating profile, Freshkote PF is safe for contact lens wearers and can be used on an as-needed basis. A nonprescription product, new Freshkote PF is available in 10-mL multidose bottles or boxes of 30 single-unit vials. Freshkote PF can be professionally recommended to patients and sold behind the pharmacy counter.
Eyevance’s acquisition of the Freshkote family of products follows the announcement of an exclusive licensing agreement with Nicox Ophthalmics for prescription-only Zerviate (cetirizine ophthalmic solution 0.24%) for the treatment of ocular itching associated with allergic conjunctivitis. Eyevance plans to launch Zerviate in early 2019.